It's Goodbye From Me - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

It's Goodbye From Me

Pharmaceutical Technology Europe
Volume 23, Issue 3

This issue will mark the last issue for me as Editor of PTE. It's time for me to move on to pastures new and to say my goodbyes. But before I do, I would like to say what a pleasure it has been for me to serve as Editor of Pharmaceutical Technology Europe. I have witnessed some very exciting but also incredibly testing times within the industry during my time as Editor, but I am in great admiration of the work that you do and some of the innovative ways that companies have adapted to withstand the impact of the significant market changes — from economic uncertainties through to patent expirations, the growth of biologics, and strong competition from emerging countries, to name just a few of the challenges. I can, however, guarantee that PTE will continue to keep you updated on all of the latest issues, developments and innovations within your market. We have an incredibly talented team here at Pharmaceutical Technology and I am confident that they will serve you to the best of their ability. I would now like to take this opportunity to thank you so much for your invaluable support of PTE and to introduce you to our very talented new Editor of PTE, Rich Whitworth.

Many thanks and very best wishes,
Fedra Pavlou, Editor-in-Chief

Let me begin by thanking Fedra for all of her hard work over the past few years, and for handing over a very healthy PTE. I am sure you will all join me in wishing her the very best for the future.

I am excited to be joining the editorial team at PTE so early in the new year and very much looking forward to having real contact with some of you wherever possible. Over the coming months, I plan to continue to nurture our active online community of readers and contributors, which offers such an important extra dimension to PTE and facilitates rapid exchange of new ideas, concerns, and hopes for the future. This online bond between reader, writer—and the editorial team—enables us to guide PTE in directions of your choosing, responding quickly to trends and issues you consider most important in this dynamic industry.

Please join us on LinkedIn (, follow us on Twitter (, and get involved!

Many thanks in advance for your continued support,
Rich Whitworth, Editor


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here